Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025

Core Insights - Kyverana Therapeutics (NASDAQ: KYTX) is preparing for multiple catalysts in the coming years, aiming to be among the first to potentially receive regulatory approval for a CAR-T therapy [2] Group 1 - The company is focused on developing CAR-T therapies, which are a type of immunotherapy used to treat certain types of cancer [2] - Kyverana Therapeutics is part of a broader trend in the biotech industry, where companies are increasingly investing in innovative therapies to address unmet medical needs [2]